Products information

For treatment of advanced gastric cancer (unresectable advanced gastric cancer) in adult by combination use with Cisplatin or as monotherapy (for patients who are intolerant to cisplatin)

• S-1 40-60mg B.I.D 2 weeks on 1 weeks off (q6w), SPIRITS Study

• S-1 40-60mg B.I.D 3 weeks on 2 weeks off + Cisplatin 60mg/m² (q5w), SPIRITS Study

Use as monotherapy for adjuvant treatment for locally advanced gastric cancer after surgery by D2-dissection.

• S-1 40-60mg B.I.D 4 weeks on 2 weeks off (q6w) 8 cycles, ACTS-GC study

For adjuvant treatment for locally advanced gastric cancer after surgery by D2-dissection with combination regimen.

• S-1 40-60mg B.I.D 2 weeks on 1 weeks off (q3w) + Oxaliplatin 130mg/m² (q3w) 8 cycles, ARTIST-2 study

• S-1 40-60mg B.I.D 2 weeks on 1 weeks off (q3w) 16 cycles + Docetaxel 40mg/m² (q3w) C2-C9, JACRO GC-07 study

For treatment of Colorectal Cancer (locally advanced or unresectable or metastasis) by combination use with Oxaliplatin for 1st line treatment and by combination use with Irinotecan for 2nd line treatment.

• S-1 40-60mg B.I.D 2 weeks on 1 week off + Oxaliplatin 130mg/m² (q3w), SOX vs COX Study

• S-1 40-60mg B.I.D day 1-7, 15-21 + Irinotecan 125mg/m² day 1, 15 (q4w), FIRIS Study

For treatment of Non-Small Cell Lung Cancer (locally advanced or unresectable or metastasis) by combination use with Carboplatin.

• S-1 40-60mg B.I.D 2 weeks on 1 week off + Carboplatin AUC5 (q3w), LETS Study

For treatment of Non-Small Cell Lung Cancer (locally advanced or unresectable or metastasis) by combination use with Cisplatin.

• S-1 40-60mg B.I.D 3 weeks on 2 weeks off + Cisplatin 60mg/m² (q5w), CATS Study

For treatment of Non-Small Cell Lung Cancer (locally advanced or unresectable or metastasis) by mono therapy after platinum base.

• S-1 40-60mg B.I.D 4 weeks on 2 weeks off (q6w), EAST-LC study

For treatment of Pancreatic Cancer (locally advanced or unresectable or metastasis) as monotherapy

• S-1 40-60mg B.I.D 4 weeks on 2 weeks off (q6w), GEST Study

For treatment of Pancreatic Cancer after resettable as monotherapy

• S-1 40-60mg B.I.D 4 weeks on 2 weeks off (q6w) 4 cycles, JASPAC-01 study

For treatment of  Breast Cancer (locally advanced or unresectable or metastasis) Her-2 negative as monotherapy

• S-1 40-60mg B.I.D 4 weeks on 2 weeks off (q6w), Select-BC study

For treatment of Biliary tract Cancer after resettable as monotherapy

• S-1 40-60mg B.I.D 4 weeks on 2 weeks off (q6w) 4 cycles, JASPAC-01 study

For treatment of Biliary tract cancer (locally advanced or unresectable or metastasis).

• S-1 40-60mg B.I.D 1 weeks on 1 weeks off (q2w) + Gemcitabine 1000mg/m²day1 + Cisplatin 25mg/m² day1, MITSUBA study

• S-1 40-60mg B.I.D 2 weeks on 1 weeks off (q2w) + Gemcitabine 1000mg/m²day1,8, FUGA-BT study

For the treatment of adult patients with metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine, oxaliplatin and irinotecan based chemotherapies, anti-VEGF agents, and anti EGFR agents.

• Recommended starting dose in adults is 35 mg/m²/dose administered orally twice daily on Days 1 to 5 and Days 8 to 12 of each 28-day cycle as long as benefit is observed or until unacceptable toxicity occurs. RECOURSE Study

For the treatment of adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy.

• Recommended starting dose in adults is 35 mg/m² /dose administered orally twice daily on Days 1 to 5 and Days 8 to 12 of each 28-day cycle as long as benefit is observed or until unacceptable toxicity occurs. TAGS Study